IL7-Receptor-Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia.

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• T-cell acute lymphoblastic leukemia (T-ALL) cells overexpress IL7 receptor alpha (IL7Rα/CD127), contributing to chemotherapy resistance and relapse.
• IL7Rα is a potential therapeutic target for T-ALL treatment.

Purpose of the Study:

• To develop and evaluate IL7Rα-targeted chimeric antigen receptor (CAR) T cells for T-ALL treatment.
• To compare the efficacy of low- and high-affinity CD127 CAR T cells.
• To address CAR T-cell fratricide and optimize CAR T-cell expansion and function.

Main Methods:

• Development of CD127-targeted CAR T cells with varying affinities (low and high).
• In vitro and in vivo testing in T-ALL models (cell lines, mouse models, patient-derived blasts).
• CRISPR-Cas9 gene editing to knock out CD127 and investigation of dasatinib for managing fratricide.

Main Results:

• CD127 CAR T cells exhibit significant antitumor efficacy against T-ALL.
• Low-affinity CD127 CAR T cells show higher efficacy than high-affinity counterparts.
• CAR T-cell fratricide was observed and strategies involving CD127 knockout or dasatinib treatment were explored to mitigate it, with dasatinib improving CAR T-cell yield and function.

Conclusions:

• IL7Rα is a viable target for CAR T-cell therapy in T-ALL.
• Low-affinity CD127 CAR T cells offer potent antitumor activity.
• Dasatinib represents a promising strategy to enhance CAR T-cell therapy for T-ALL by managing fratricide and improving cell fitness.